Myelodysplastic/myeloproliferative neoplasm, NOS

Haematolymphoid Tumours (5th ed.)

editHAEM5 Conversion Notes

This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable.

Primary Author(s)*

Ruth MacKinnon PhD

Victorian Cancer Cytogenetics Service

Melbourne, Australia

Cancer Category / Type

Myelodysplastic/Myeloproliferative Neoplasm (MDS/MPN)

Cancer Sub-Classification / Subtype

Myelodysplastic / myeloproliferative neoplasm, unclassifiable (MDS/MPN-U)

Definition / Description of Disease

MDS/MPN-U are a heterogeneous group of myeloid neoplasms meeting the criteria for MDS/MPN at onset, without the defining features of one of the other categories of MDS/MPN, i.e. chronic myelomonocytic leukaemia (CMML) juvenile myelomonocytic leukaemia (JMML), atypical chronic myeloid leukaemia, BCR-ABL1-negative (aCML) or myelodysplastic / myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

MDS/MPN-U is the most poorly characterised of the MDS/MPN subgroups .

• < 20% blasts in the peripheral blood and bone marrow
• Clinical and morphological features of a category of MDS
  • excluding any case meeting the criteria for MDS with isolated del(5q)
• Platelet count of ≥ 450 ×10/L with bone marrow megakaryocytic proliferation and/or a white bood cell count of ≥ 13 × 10⁹/L
• Myelodysplastic / myeloproliferative features not explained by recent cytotoxic or growth factor therapy
• Excludes cases with PDGFRA, PDGFRB and FGFR1 rearrangement and PCM1-JAK2

When an underlying MPN has not been identified, the category of MDS/MPN-U is appropriate.

Cases with features of MDS/MPN-U may arise due to prior exposure to treatment and are included in the Therapy-related myeloid neoplasms (t-MN).

Well-defined MPN which subsequently develop dysplastic features and progress to a more aggressive phase are excluded from this category.

Palomo et al. proposed sub-categories of MDS/MPN-U based on the molecular signature. See Gene Mutations below.

Synonyms / Terminology

• Chronic myelodysplastic / myeloproliferative disease (no longer used)
• Mixed myeloproliferative / myelodysplastic syndrome, unclassifiable
• Overlap syndrome, unclassifiable

Epidemiology / Prevalence

• Less than 5% of myeloid malignancies
• Median age: reports vary from 70 to 75
• Male:female ratio 2:1

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table)

Signs and Symptoms	EXAMPLE Asymptomatic (incidental finding on complete blood counts) EXAMPLE B-symptoms (weight loss, fever, night sweats) EXAMPLE Fatigue EXAMPLE Lymphadenopathy (uncommon)
Laboratory Findings	EXAMPLE Cytopenias EXAMPLE Lymphocytosis (low level)

editv4:Clinical Features

The content below was from the old template. Please incorporate above.

• Overlap with MDS and MPN
• Clinically the most heterogeneous of the MDS/MPN
• Does not have features that define it as belonging to any of the other categories of MDS/MPN

Sites of Involvement

• Peripheral blood and bone marrow always involved
• Extramedullary tissues may be involved

Morphologic Features

Co-occurrence of myeloid lineages with (i) ineffective and/or dysplastic proliferation and (ii) effective proliferation with or without dysplasia

• Usually with anaemia, with or without macrocytosis
• Thrombocytosis (platelets ≥ 450 x 10⁹/L) or leucocytosis (white blood cells ≥ 13 x 10⁹/L)
• Dysgranulopoiesis in about 50% of cases
• Giant or hypogranular platelets in some
• Dysmegakaryopoiesis with megakaryocytes resembling those in MDS in >50% of cases, otherwise varying proportions of MDS-like and MPN-like megakaryocytes
• No dysmegakaryopoiesis in <10% of cases
• Blasts < 20% in bone marrow and peripheral blood
• Proliferation in any or all of myeloid lineages in bone marrow biopsy
• ≥ 10% of at least one cell line

Palomo et al.'s MDS/MPN-U sub-categories defined by molecular profile (see Gene Mutations below) tend to have:

• CMML-like: higher monocyte count
• aCML-like: higher white blood cell count
• MDS/MPN-RS-T-like: higher ring sideroblast percentage
• TP53: more anaemia and higher blast percentage
• other: JAK2 mutations correlated with thrombocytosis

Immunophenotype

Put your text here and fill in the table (Instruction: Can include references in the table)

Finding	Marker
Positive (universal)	EXAMPLE CD1
Positive (subset)	EXAMPLE CD2
Negative (universal)	EXAMPLE CD3
Negative (subset)	EXAMPLE CD4

editv4:Immunophenotype

The content below was from the old template. Please incorporate above.

May be similar to that of MDS or MPN

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement	Genes in Fusion (5’ or 3’ Segments)	Pathogenic Derivative	Prevalence	Diagnostic Significance (Yes, No or Unknown)	Prognostic Significance (Yes, No or Unknown)	Therapeutic Significance (Yes, No or Unknown)	Notes
EXAMPLE t(9;22)(q34;q11.2)	EXAMPLE 3'ABL1 / 5'BCR	EXAMPLE der(22)	EXAMPLE 20% (COSMIC) EXAMPLE 30% (add reference)	Yes	No	Yes	EXAMPLE The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).

editv4:Chromosomal Rearrangements (Gene Fusions)

The content below was from the old template. Please incorporate above.

• None identified
• BCR-ABL1 fusion should be excluded
• Absence of PDGFRA, PDGFRB and FGFR1 rearrangements, absence of PCM1-JAK2 fusion

editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).

Please incorporate this section into the relevant tables found in:

• Chromosomal Rearrangements (Gene Fusions)
• Individual Region Genomic Gain/Loss/LOH
• Characteristic Chromosomal Patterns
• Gene Mutations (SNV/INDEL)

• Prognosis is variable and not well documented
• There are few data regarding an appropriate prognostic scoring system , but IPSS-R or IPSS have been prognostically useful
• Median overall survival (OS) from various reports: 80 months ; 21.8 months ; 12 months
• Leukaemia-free survival: 18.9 months ; 10.8 months
• Leukaemic transformation: 10% ; 16% after a median of 10.8 months ; 
  • ASXL1/SRSF2 co-mutation is a significant risk factor
• Abnormal karyotype associated with inferior OS
• ASXL1, EZH2, STAG2 mutations associated with shorter OS
• Targeted sequencing may be useful for assessing prognostic impact and making clinical decisions .
  • Molecular classification into sub-categories had the strongest prognostic impact in a study by Palomo et al. :
    • MDS/MPN-RS-T-like: most favourable prognosis
    • aCML-like: high risk
    • "TP53": least favourable prognosis
• “Treatment is based on therapies used for MDS or MPN and is guided by symptoms and/or cytopenias” and can include growth factors for leukocytosis or cytoreductive therapies for cytopenias .

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.)

Chr #	Gain / Loss / Amp / LOH	Minimal Region Genomic Coordinates [Genome Build]	Minimal Region Cytoband	Diagnostic Significance (Yes, No or Unknown)	Prognostic Significance (Yes, No or Unknown)	Therapeutic Significance (Yes, No or Unknown)	Notes
EXAMPLE 7	EXAMPLE Loss	EXAMPLE chr7:1- 159,335,973 [hg38]	EXAMPLE chr7	Yes	Yes	No	EXAMPLE Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
EXAMPLE 8	EXAMPLE Gain	EXAMPLE chr8:1-145,138,636 [hg38]	EXAMPLE chr8	No	No	No	EXAMPLE Common recurrent secondary finding for t(8;21) (add reference).

editv4:Genomic Gain/Loss/LOH

The content below was from the old template. Please incorporate above.

One study identified very few recurrent gains and losses below the level of cytogenetic detection .

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)

Chromosomal Pattern	Diagnostic Significance (Yes, No or Unknown)	Prognostic Significance (Yes, No or Unknown)	Therapeutic Significance (Yes, No or Unknown)	Notes
EXAMPLE Co-deletion of 1p and 18q	Yes	No	No	EXAMPLE: See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Aberrations / Patterns

The content below was from the old template. Please incorporate above.

• None specific to MDS/MPN-U
• Abnormal karyotype 43% across four studies (11/38 ; 48/102 ; 23/65 ; 43/85 )
• Complex karyotype 10% across three studies (12/102 ; 2/65 ; 10/85 )
• Specific abnormalities:
  • Isochromosome of 17q (commonly referred to as i(17q) but correctly written as i(17)(p11.2)) has gain of 17q, gain of 17p from the 17p11.2 breakpoint to the centromere; and loss of 17p from the telomere to the 17p11.2 breakpoint, including TP53 . It is the only cytogenetic abnormality mentioned in the MDS/MPN-U section of the 2016 edition of the WHO classification . It is well documented in MDS/MPN with some cases meeting the criteria for atypical CML (aCML), and others justifying an MDS/MPN-U classification . Data on incidence are rare; one case in 65 was reported in one study (1.5%) . Six cases were reported in a series of 551 MDS/MPN which included both aCML and MDS/MPN-U . Meggendorfer et al found a highly significant association between i(17q) and SETBP1 mutations. SETBP1 mutation is strongly correlated with aCML , and was found in about a third of the aCML-like subcategory of MDS/MPN-U .
  • + 8
    • 23% across two studies (26/102 ; 12/65 )
    • isolated +8, 16% across two studies (17/102 ; 13/85 )
  • -7/del(7q)
    • 10% across two studies (12/102 ; 4/65 )
    • isolated -7/del(7q), 5% (5/102 )

• Excludes any case with isolated del(5q) (even if JAK2 is mutated) - these should be classified as MDS with isolated del(5q).

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)

Gene; Genetic Alteration	Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)	Prevalence (COSMIC / TCGA / Other)	Concomitant Mutations	Mutually Exclusive Mutations	Diagnostic Significance (Yes, No or Unknown)	Prognostic Significance (Yes, No or Unknown)	Therapeutic Significance (Yes, No or Unknown)	Notes
EXAMPLE: TP53; Variable LOF mutations EXAMPLE: EGFR; Exon 20 mutations EXAMPLE: BRAF; Activating mutations	EXAMPLE: TSG	EXAMPLE: 20% (COSMIC) EXAMPLE: 30% (add Reference)	EXAMPLE: IDH1 R123H	EXAMPLE: EGFR amplification				EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).

Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

editv4:Gene Mutations (SNV/INDEL)

The content below was from the old template. Please incorporate above.

Amongst the MDS/MPN subtypes, MDS/MPN-U has the most heterogeneous mutation profile. In one study it was most strongly correlated with U2AF1 and TP53 mutations .

No mutations are specific for any MDS/MPN, including MDS/MPN-U .

The WHO in 2017 listed TET2, NRAS, RUNX1, CBL, SETBP1 and ASXL1 as having relatively high mutation frequencies. Frequencies* of these and the other most common mutations given in recent publications are:

• ASXL1: 29%* ; 53%
• TET2: 27% ; 37%
• JAK2: 25% ; 25%
  • V617F ; 18%
• SRSF2: 23% ; 23%
  • P95 residue
• EZH2: 17% ; 25%
• U2AF1: 13% ;19%
  • most mutatons in Q157
• RUNX1: 13% ; 17%
• SF3B1: 12% 11%
• ZRSR2: 11% ; 5%
• SETBP1: 11% ;12%
• NRAS: 10% ; 4%
• DNMT3A: 9% ; 13%
• TP53: 8% ;12%
• STAG2: 5% ; 16%
• CSF3R: 5% ; 5%
• ZBTB33: 5%
  • novel to MDS/MPN-U
• CBL: 4% ; 6%

*Frequencies from Figure 1 in are given, since the list in the text does not include all of these genes (the values in the text do not match the values in Figure 1).

Palomo et al identified specific mutation combinations that mimicked the other MDS/MPN subtypes and allowed MDS/MPN-U to be assigned to one of five MDS/MPN-U sub-categories :

(The first three are most similar to one of the three other adult subgroups of MDS/MPN)

1. CMML-like (TET2/SRSF2)
2. aCML-like (ASXL1/EZH2)
3. MDS/MPN-RS-T-like (SF3B1 or DNMT3A/SF3B1)
4. TP53 sub-category (mono- or bi-allelic TP53 mutation; more anaemia and higher blast count)
5. other (no distinctive signature but enriched for U2AF1, JAK2, ASXL1 mutations; JAK2 mutations correlated with thrombocytosis)

Other Mutations

The presence of TET2, NRAS, RUNX1, CBL, SETBP1 or ASXL1 mutation may help confirm a suspected diagnosis .

If a SF3B1 mutation is present, consider whether it is MDS/MPN-RS-T or progression from MDS with ring sideroblasts .

MPN driver mutations (e.g. JAK2, MPL or CALR mutation) may be present, but if pre-existing MPN is not documented, an MDS/MPN-U designation is justified .

There is a significant likelihood of AML developing if there is ASXL1 and SRSF2 co-mutation .

Epigenomic Alterations

Not known

Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table.)

Gene; Genetic Alteration	Pathway	Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations	EXAMPLE: MAPK signaling	EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations	EXAMPLE: Cell cycle regulation	EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations	EXAMPLE:  Histone modification, chromatin remodeling	EXAMPLE:  Abnormal gene expression program

editv4:Genes and Main Pathways Involved

The content below was from the old template. Please incorporate above.

• Major drivers / early mutations in epigenetic regulators (ASXL1, TET2) and splicing factors (SRSF2)
• Secondary mutations in signaling pathway genes (JAK2)

Genetic Diagnostic Testing Methods

• Bone marrow aspirate
• Full blood count
• Cytogenetics

Familial Forms

Not known

Additional Information

Refractory anemia with ring sideroblasts and thrombosis (RARS-T) fell within this category prior to the 2016 WHO edition but now forms a distinct category, MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).

Links

Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page (Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "http://www." portion.)

References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome. *Citation of this Page: “Myelodysplastic/myeloproliferative neoplasm, NOS”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/7/2023, https://ccga.io/index.php/HAEM5:Myelodysplastic/myeloproliferative_neoplasm,_NOS.